NCT06547476尚未招募2 期
A Phase 2, Single Arm Study Investigating the Use of Chidamide and PD-1 Antibody Combination With Anlotinib in HER2-low, Unresectable and/or Metastatic Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 40
- 主要终点
- Progression-free survival(PFS)
研究概览
简要总结
This Phase II study was designed to assess the efficacy and safety of the combination of PD-1 inhibitor, Tucidinostat (chidamide), a histone deacetylase inhibitor, and anlotinib in advanced breast cancer.
Participants must have HER2-low and PD-L1 positive （CPS≥1）breast cancer that has been treated before.
Participants' cancer:
Cannot be removed by an operation Has spread to other parts of the body
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Has pathologically documented breast cancer that:
- •Is unresectable or metastatic
- •Has low-HER2 expression defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested)
- •Is HR-positive
- •Has progressed on, and would no longer benefit from, endocrine therapy
- •Has been treated with 0 to 1 prior lines of chemotherapy in the recurrent or metastatic setting
- •Was never previously HER2-positive (ICH 3+ or ISH+) on prior pathology testing (per American Society of Clinical Oncology-College of American Pathologists [ASCO-CAP] guidelines)
- •PD-L1 positive （CPS≥1）
- •Has documented radiologic progression (during or after most recent treatment)
- •Has adequate archival tumor samples available or is wiling to provide fresh biopsies prior to randomization for:
- •assessment of HER2 status
- •assessment of post-treatment status
- •Has at least 1 measurable lesion per Response Evaluation Criteria In Solid Tumors 1.1
- •Has protocol-defined adequate cardiac, bone marrow, renal, hepatic and blood clotting functions
- •Male and female participants of reproductive/childbearing potential, agrees to follow instructions for method(s) of contraception and agrees to avoid preserving ova or sperm for at least 4.5 months after treatment (or longer, per locally approved labels)
排除标准
- •Allergies to any monoclonal antibody or tucidinostat preparation have been known, and hypersensitivity reactions of more than 3 levels have occurred
- •Previously received histone deacetylase inhibitors,or immune checkpoint inhibitor, or angiogenesis inhibitors.
- •Subjects with any active, known or suspected autoimmune disease or history of autoimmune disease.
- •Known active CNS metastases and/or carcinomatous meningitis.
- •Received a live vaccine within 4 weeks of the first dose of study medication.
- •Major surgery received or severe traumatic injury, fracture, or ulcer occurred within 4 weeks of the first dose of study medication.
- •Pregnant or lactating female.
- •Uncontrolled clinically significant systemic diseases, including active infection, unstable angina, angina occurred within 3 months,≥ NYHA II congestive heart failure, myocardial infarction occurred within 6 months, severe arrhythmia, liver, kidney, or metabolic disease.
- •Participate in other clinical trials currently or within 4 weeks prior to enrollment.
研究组 & 干预措施
Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), Anlotinib
Experimental
干预措施: Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), anlotinib (Drug)
结局指标
主要结局
Progression-free survival(PFS)
时间窗: 2 years
Time from treatment until disease progression or death
次要结局
- Clinical Benefit Rate (CBR)(2 years)
- Objective Response Rate（ORR）(2 years)
- Disease Control Rate （DCR）(2 years)
- Overall survival (OS)(2 years)
研究者
Kun Wang
Professor
Guangdong Provincial People's Hospital
相似试验
尚未招募
2 期
Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lung Cancer: a Single-arm, Multicenter Clinical StudySquamous Non-Small Cell Lung Cancer SqNSCLCNCT06747169Jian-Guo Zhou, MD, PhD32
招募中
不适用
A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ CancerGastric Cancer/Adenocarcinoma of Esophagogastric JunctionNCT06158919Fudan University58
进行中（未招募）
2 期
PD-1 Antibody Therapy + Infliximab for Metastatic MelanomaMetastatic MelanomaNCT05034536Massachusetts General Hospital36
招募中
2 期
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction AdenocarcinomaEsophagogastric Junction AdenocarcinomaGastric CancerNCT06461910Zekuan Xu30
已完成
2 期
A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer PatientsNon-Small Cell Lung Cancer NSCLCNCT02879617Academic Thoracic Oncology Medical Investigators Consortium47